Philadelphia, PA – PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record.

At the core of PCI’s investment plan is a $100 million project at its San Diego campus, featuring a high-speed isolator filling line for ready-to-use (RTU) prefilled syringes and cartridges. Scheduled to be operational in the first half of 2028, the line will more than double the site's existing syringe and cartridge filling capacity. It will be PCI’s second isolator fill-finish line in San Diego, which currently supports and manufactures over 45 FDA-approved products. The campus also hosts large-scale aseptic filling for prefilled syringes and cartridges, alongside specialized capabilities in oligonucleotides, peptides, complex formulations and lyophilization for injectables such as nanoparticles, mRNA, mAbs, proteins, and highly potent products.

Meanwhile, PCI’s Bedford, New Hampshire campus is commissioning a GMP-ready bespoke isolator vial and lyophilization line that, upon commencing full-scale production this month, will be capable of producing batch sizes of up to 300,000 vials at 400 units per minute, for an annual total of 33 million – among the most robust, state-of-the-art setups of its kind in the US. The campus also will commission a customer-dedicated high-potent sterile fill-finish line slated to be one of a kind in the US.